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Correlation between Calprotectin and Oxidized LDL in
Preeclampsia
Aim: To evaluate the relationship between serum calprotectin and oxidized low density lipoprotein (LDL) in
preeclamptic patients. Additionally, we aimed to measure serum malondialdehyde (MDA) levels as an oxidative
stress marker.
Materials and Methods: Serum calprotectin, oxidized LDL, and MDA levels were measured in a crosssectional study of 61 preeclamptic patients (39 severe preeclampsia and 22 mild preeclampsia cases) and 20
healthy pregnant subjects. Serum MDA concentration was measured with spectrophotometric methods, and
oxidized LDL and calprotectin were measured via enzyme-linked immunoassay (ELISA).
Results: Serum calprotectin (P < 0.0001 and P = 0.014) and MDA (P = 0.001 and P = 0.028) levels were
significantly higher in the severe and mild preeclampsia groups than in the healthy control group. Serum
oxidized LDL concentration was slightly higher, but not did reach a statistically significant level, in the severe
preeclampsia group than in the healthy pregnant group (P = 0.2). There was a significant negative correlation
between the levels of calprotectin and oxidized LDL (r = –0.34, P = 0.006) in the mild and severe preeclampsia
groups. The correlation between calprotectin and MDA was not statistically significant (P = 0.08).
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Conclusions: The findings suggest that increased calprotectin is associated with preeclampsia. Further study
is necessary in order to determine whether or not high calprotectin levels prevent oxidation of circulating LDL
in preeclampsia cases.
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Preeklampside Kalprotektin ve Okside LDL Arasındaki İlişki
Amaç: Bu çalışmada preeklamptik hastalarda serum kalprotektin ve okside düşük dansiteli lipoprotein (LDL)
arasındaki ilişki araştırıldı. Ayrıca oksidatif stress markeri olarak serum malondialdehit (MDA) düzeylerinin
ölçümü yapıldı.
Yöntem ve Gereç: Bu amaçla 61 preeklamptik hasta (39 şiddetli preeklampsi ve 22 hafif preeklampsi hastası)
ve 20 sağlıklı gebe kadında (kontrol) serum kalprotektin ve okside LDL konsantrasyonları ELISA metodu ile,
MDA konsantrasyonu ise spektrofotometrik metodla ölçüldü.
Bulgular: Şiddetli ve hafif preeklampsi gruplarında serum kalprotektin (P < 0,0001 ve P = 0,014) ve MDA
(P = 0,001 ve P = 0,028) konsantrasyonları kontrol grubuna gore anlamlı olarak yüksekti. Kontrol grubuna
göre şiddetli preeklampsi grubunda, serum okside LDL konsantrasyonlarında hafif (fakat istatistiki olarak
önemli olmayan) bir artış vardı. Total preeklampsi grubunda kalprotektin ile okside LDL arasında önemli ve
negatif bir korelasyon gözlendi (r = –0,34, P = 0,006).
Sonuç: Çalışmadan elde edilen sonuçlar kalprotektin düzeylerinin artışının preeklampsi ile birlikte olabileceğini
göstermektedir ve bu hastalarda kalprotektin artışının dolaşımda bulunan LDL moleküllerinin oksidasyonunu
önleyip önlemediği araştırılmalıdır.
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Introduction
Preeclampsia is a common disease of human pregnancy and a leading cause of both
maternal morbidity and neonatal mortality (1). Inadequate or failed trophoblast invasion
and consecutively deficient remodeling of spiral arteries are associated with
preeclampsia. Numerous theories on the pathophysiological mechanisms are currently
discussed, but the etiology and pathogenesis of preeclampsia are not fully understood.
In the pathogenesis of preeclampsia, endothelial dysfunction and inflammation appear to
play major roles. An increased level of pro-inflammatory cytokines in the circulation of
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preeclamptic women, and maternal circulating activated
leukocytes and monocytes may contribute to the
processes (2,3).
Additionally, reduced invasion of the trophoblast into
the uterus and its spiral arteries are characteristic of this
disorder; thus, blood supply to the placenta is greatly
reduced. This situation leads to placental hypoxia,
followed by placental oxidative stress and dysfunction. If
the level of reactive oxygen species (ROS) exceeds the
antioxidant capacity or if antioxidant levels decline, which
may be associated with preeclampsia (4,5), then oxidative
stress will occur. ROS increase the levels of lipid
peroxidation products, namely MDA. Lipid peroxidation
may cause peroxidative damage to the vascular
endothelium and this situation may be associated with
clinical symptoms in preeclampsia (6). Increased oxidative
stress may lead to LDL oxidation, and oxidized LDL
contributes to endothelial injury and, in turn, dysfunction
in preeclampsia. In preeclampsia, increased (7,8) normal
(9), or low (10) serum oxidized LDL levels have been
reported.
Inflammation plays a crucial role in the pathogenesis
of preeclampsia. Inflammatory markers, such as Creactive protein, are associated with preeclampsia (11).
Calprotectin, a protein composed of 2 subunits of 8 and
14 kD, respectively, is released by neutrophils in the
biological fluids under inflammatory states. Calprotectin
appears to play a regulatory role in the inflammatory
process and functions in both an antimicrobial and
antiproliferative capacity (12). Studies related to serum
calprotectin report that calprotectin levels were higher in
preeclampsia patients than in normal pregnant women
(13,14). The aim of the present study was to investigate
the relationship between serum calprotectin and oxidized
LDL in preeclamptic patients.

Materials and Methods
The case-control study included 61 preeclamptic
patients (39 severe preeclampsia and 22 mild
preeclampsia cases) and 20 healthy pregnant subjects.
Healthy pregnant subjects were matched with the
preeclamptic patients on the basis of maternal age and
gestational age at the time blood was drawn. None of the
women were current smokers. Preeclampsia was defined
as the development of hypertension with proteinuria
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(15). Hypertension was defined as either systolic blood
pressure greater than 140 mmHg or diastolic blood
pressure greater than 90 mmHg on 2 consecutive
measurements at least 6 h apart. Proteinuria was defined
as excretion of greater than 300 mg of protein in a 24-h
urine collection. Preeclampsia was classified as either mild
or severe. Patients with preeclampsia were considered to
have mild preeclampsia unless they developed any of the
following (in which case they were classified as having
severe disease): blood pressure greater than 160/110
mmHg on 2 consecutive measurements 6 h apart or
greater than 5 g of protein excreted in a 24-h urine
sampling. Written informed consent was obtained from
all the participants, according to the criteria of the
Atatürk University Medical Faculty Ethics Committee.
Venous blood samples were collected into tubes
without anticoagulant. Serum was separated by
centrifugation after clotting and stored at –80 °C until
assayed. Serum MDA levels were determined
spectrophotometrically, according to the method
described by Ohkawa (16). A mixture of 8.1% sodium
dodecyl sulfate, 20% acetic acid, and 0.9% thiobarbituric
acid was added to 0.2 ml of serum, and then distilled
water was added to the mixture to bring the total volume
up to 4 ml. This mixture was incubated at 95 °C for 1 h.
Following incubation, the tubes were left to cool under
cold water and 1 ml of distilled water plus 5 ml of nbutanol/pyridine (15:1, v/v) were added, followed by
mixing. The samples were centrifuged at 4000 g for 10
min. The supernatants were removed, and absorbance
was measured with respect to a blank at 532 nm. Lipid
peroxide levels were expressed as μmol/l. Calprotectin
and oxidized LDL levels were measured with an
Immunodiagnostik AG (Bensheim, Germany) ELISA kit,
according to manufacturers’ recommendations.
Statistical Analysis
As the variances were not homogeneous,
nonparametric statistical methods were used. To
compare nonparametric variables among the 3 study
groups, Kruskal-Wallis analysis was performed. The
Mann-Whitney U-test was used as a post hoc test.
Spearman’s rank order correlation testing was performed
to calculate correlation coefficients. All statistical analyses
were performed using SPSS v.10.0.
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Results

Discussion

The clinical characteristics of the 3 study groups are
described in Table 1. The severe preeclampsia group had
significantly higher systolic and diastolic blood pressure
than the mild preeclampsia (P < 0.0001 for both) and
healthy control groups (P < 0.0001 for both). Serum
calprotectin (P < 0.0001 and P = 0.014) and MDA (P =
0.001 and P = 0.028) levels were significantly higher in
the severe and mild preeclampsia groups than in the
healthy control group (Table 2). Serum oxidized LDL
concentrations were slightly higher in the severe
preeclampsia group than in the healthy pregnant group,
but the difference was not statistically significant (P =
0.2). There were no significant differences between the
severe and mild preeclampsia groups with respect to
oxidized LDL. There was a significant negative correlation
between the levels of calprotectin and oxidized LDL (r =
–0.34, P = 0.006) in combined preeclampsia group (mild
and severe preeclampsia). The correlation between
calprotectin and MDA was not statistically significant (P =
0.08).

In the present study normal levels of oxidized LDL,
and elevated calprotectin and MDA were observed in the
severe and mild preeclamptic patients, as compared to the
control subjects. Additionally, the results show a negative
correlation between calprotectin and oxidized LDL in
preeclamptic patients.
Some investigators have determined elevated levels of
oxidative stress markers, such as MDA, in preeclamptic
patients that are consistent with the present study’
findings (7,17,18). The causes of increased oxidative
stress in these patient groups are variable. One of the
causes may be neutrophil activation. Neutrophils play an
important role in the innate immune response to infection
in mammals. Stimuli, such as infection and injury, induce
the activation of neutrophils, which respond via
phagocytosis and the release of antimicrobial peptides.
Although mild neutrophil activation is known to occur
during normal pregnancy, neutrophil activation is greater
in preeclamptic pregnancies than in normal pregnancies
(19,20). Mellembakken et al. (21) showed that

Table 1. Clinical characteristics of the study groups.
Severe preeclampsia
(n = 39)

Mild preeclampsia
(n = 22)

Normal pregnancy
(n = 20)

Gestational age (weeks)

36.84 ± 1.61

36.77 ± 1.90

36.70 ± 2.00

Maternal age (years)

26.49 ± 4.81

26.59 ± 4.90

25.20 ± 4.06

172.95 ± 9.92

1

1

121.44 ± 6.71

112.44 ± 5.95

1

1

65.50 ± 9.45

Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)

145.00 ± 4.88

95.91 ± 4.79

Results are given as mean ± SD. 1P < 0.0001 compared to the normal pregnancy group.

Table 2. Serum calprotectin, oxidized LDL, and MDA concentrations in the study groups.

Calprotectin (ng/ml)

Severe preeclampsia
(n = 39)

Mild preeclampsia
(n = 22)

Normal pregnancy
(n = 20)

2006.00 ± 1177.601

1677.49 ± 1222.09 2

772.14 ± 451.42

Oxidized LDL (ng/ml)

197.08 ± 55.85

189.22 ± 52.46

MDA (μmol/l)

3.99 ± 1.523

3.91 ± 1.864

178.61 ± 54.04
2.67 ± 1.11

Results are given as mean ± SD. 1P < 0.0001; 2P = 0.014; 3P = 0.001; 4P = 0.028 compared to the normal
pregnancy group.
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expression of neutrophil activation markers was
enhanced on cells from the uterus of preeclampsia
patients. It is well known that various ROS and
metabolites are generated during the respiratory burst of
activated neutrophils. ROS produced by neutrophils may
affect vascular tone directly by contracting smooth
muscle tissue (22).
Calprotectin is present in high concentrations in
neutrophils and can be released by activated cells at
inflammatory sites (23-25). The heterocomplex consists
of 2 proteins—calgranulin A and calgranulin B.
Calprotectin plays a role in various physiological
functions, such as inflammatory processes and
antiproliferation of cells, as well as in the defense of
neutrophils against bacterial infections. Elevated
calprotectin levels have been observed at many sites of
inflammation and in the extracellular fluid of patients
with many types of inflammatory conditions, including
rheumatoid arthritis (26) and ulcerative colitis (27). It
may also be an important mediator, along with multiple
regulatory functions, in inflammatory reactions such as
preeclampsia. In the present study, while serum oxidized
LDL levels were normal, calprotectin levels were higher in
both preeclampsia groups than in the healthy pregnant
group; in the combined preeclampsia group there was a
negative correlation between calprotectin and oxidized
LDL.
Furthermore, in a recent study on protein mapping in
LDL, calgranulin A, a component of calprotectin, was
detected in LDL and it was speculated that calgranulin A
might play a role as a natural scavenger in LDL,
preventing LDL oxidation (28). Here, we can now ask this
question: is calprotectin also a circulatory antioxidant?
The probable antioxidant role of this protein complex
awaits further investigation.
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In the present study, in contrast to MDA, no
modifications were observed in the level of oxidized LDL
in any of the study groups. Oxidized LDL cholesterol
serves as a marker of both systemic and vascular
oxidative stress, and inflammation. Importantly, modified
LDL itself is able to induce inflammation, as it induces
adhesion to endothelial cells and the oxidative potential of
cells in the vascular wall, thus influencing early
atherogenesis (29,30).
Studies of serum oxidized LDL levels in preeclampsia
are inconsistent; some investigators reported significantly
higher levels in preeclamptic women than in healthy
pregnant women (7,8), whereas Belo et al. (9) did not
observe any differences in plasma levels of oxidized LDL.
Nonetheless, in the present study the oxidized LDL to
LDL-cholesterol ratio was significantly higher in the
preeclampsia group than in the normal pregnancy group,
which suggests that the proportion of LDL that was
oxidized was higher. On the other hand, Rajimekers et al.
(10) reported that women with preeclampsia had lower
oxidized LDL levels than healthy pregnant women that
were matched according to gestational age. Additionally,
they did not observe any differences in MDA
concentration between the 2 groups. In contrast to some
previous reports, in the present study serum oxidized LDL
levels in the preeclamptic women were not different than
those in the controls. Interestingly, calprotectin and
oxidized LDL were negatively correlated, which could
mean that normal oxidized LDL levels were due to an
increase in calprotectin.
In conclusion, in preeclamptic patients serum
calprotectin levels increased and oxidized LDL was
negatively correlated with calprotectin. Further detailed
studies are necessary to determine if calprotectin can
prevent oxidation of circulating LDL molecules.
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